Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #141996 on Biotech Values
DewDiligence
05/16/12 9:59 AM
#142015 RE: linhdtu #141996
Sanofi's current strategy is to extend the Lantus franchise by developing a titratable single-pen injection formulation of Lantus+Lyxumia, but movement into Phase III has been delayed several times and currently is expected to advance in 2013. That would put Sanofi behind Novartis’ Ideglira fixed-dose combination of Victoza and Degludec, for which data is likely to be published in July or August.